The hepatitis C treatment drug Klopevir Hydrochloride Capsules was approved for marketing!
-
Last Update: 2020-02-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On February 12, the State Food and Drug Administration issued a notice saying that recently, the State Food and Drug Administration approved the listing of clopevir hydrochloride capsule (trade name: kailiwei), a class 1 innovative drug of Beijing kaiyingerling Biotechnology Co., Ltd., through the priority review and approval procedure This product is used in combination with sophibuvir in the treatment of adult chronic hepatitis C virus (HCV) infection of gene 1, 2, 3 and 6, which is initially treated or treated with interferon It may or may not be combined with compensatory cirrhosis Clopevir hydrochloride is an NS5A inhibitor, which blocks the replication and assembly of HCV by inhibiting NS5A protein The marketing of clopevir hydrochloride capsule is helpful to increase the accessibility of domestic anti HCV drugs and meet the clinical drug demand Adorable adorable
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.